TY - JOUR
T1 - Optimal use of L‐asparaginase (NSC‐109229) in acute lymphocytic leukemia
AU - Jones, Barbara
AU - Holland, James F.
AU - Glidewell, Oliver
AU - Jacquillat, Claude
AU - Weil, Marise
AU - Pochedly, Carl
AU - Sinks, Lucius
AU - Chevalier, Louise
AU - Maurer, Harold M.
AU - Koch, Kjell
AU - Falkson, Geoffrey
AU - Patterson, Richard
AU - Seligman, Barbara
AU - Sartorius, Jurg
AU - Kung, Faith
AU - Haurani, Farid
AU - Stuart, Marie
AU - Burgert, E. Omer
AU - Ruymann, Frederick
AU - Sawitsky, Arthur
AU - Forman, Edwin
AU - Pluess, Hansjuerg
AU - Truman, John
AU - Hakami, Nasrollah
PY - 1977
Y1 - 1977
N2 - Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.
AB - Between 1971 and 1974, 646 evaluable patients under 20 years of age with previously untreated acute lymphocytic leukemia were treated according to Cancer and Leukemia Group B (formerly Acute Leukemia Group B) Protocol 7111. On a random basis, they received a 10‐day course of 1,000 units/kg/day of L‐asparaginase before, during, or after a 3‐week course of vincristine and corticosteroid. A control group received vincristine and corticosteroid for 4 weeks but no asparaginase. The overall complete remission rate was 85%, which was not altered significantly by any of the induction variables. Patients who received asparaginase for 10 days subsequent to vincristine and corticosteroid had a significantly longer complete remission duration with an estimated median of 45 months, compared to 20 months for the group receiving no asparaginase and 27 months for the other 2 asparaginase regimens. The beneficial effect of asparaginase was noted, irrespective of which 1 of the 2 intensification and maintenance programs the patients received. The 5‐year projection indicates a complete remission rate of 50% for those patients receiving subsequent asparaginase as compared to 41% of those induced on other regimens in this study and thus is superior to the use of only vincristine and corticosteroid.
UR - http://www.scopus.com/inward/record.url?scp=0017662049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017662049&partnerID=8YFLogxK
U2 - 10.1002/mpo.2950030410
DO - 10.1002/mpo.2950030410
M3 - Article
C2 - 337095
AN - SCOPUS:0017662049
VL - 3
SP - 387
EP - 400
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
SN - 1545-5009
IS - 4
ER -